The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Targeted therapies in newly diagnosed AML: BCL2, FLT3 and IDH inhibitors
Catherine Lai, MD, MPH, University of Pennsylvania, Philadelphia, PA, reflects on targeted therapies in the management of newly-diagnosed acute myeloid leukemia (AML), including BCL2, FLT3, and IDH inhibitors, as well as combination approaches, mutation agnostic factors, and toxicities. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
